AstraZeneca Market Cap 2010-2023 | AZN

AstraZeneca market cap history and chart from 2010 to 2023. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. AstraZeneca market cap as of April 18, 2024 is $211.94B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $211.944B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $708.775B 118.03
Novo Nordisk (NVO) Denmark $550.845B 45.38
Johnson & Johnson (JNJ) United States $351.202B 13.93
Merck (MRK) United States $317.211B 83.49
AbbVie (ABBV) United States $291.555B 14.82
Novartis AG (NVS) Switzerland $196.211B 13.59
Pfizer (PFE) United States $143.772B 13.87
Sanofi (SNY) $114.819B 10.34
Innoviva (INVA) United States $0.929B 6.56